These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 1720441)
1. Investigation and prevention of artifactual staining in flow cytometric analyses of whole blood samples from patients treated with H65-RTA, an anti-CD5 monoclonal antibody conjugated to ricin A chain. Fishwild DM; Saria EA J Immunol Methods; 1991 Nov; 144(1):27-34. PubMed ID: 1720441 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of an anti-CD5-ricin A chain immunoconjugate in an improved human peripheral blood lymphocyte--reconstituted severe combined immunodeficient mouse model. Kohn FR; Fishwild DM; Kung AH Int J Immunopharmacol; 1993 Aug; 15(6):695-709. PubMed ID: 7691766 [TBL] [Abstract][Full Text] [Related]
3. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. LeMaistre CF; Rosen S; Frankel A; Kornfeld S; Saria E; Meneghetti C; Drajesk J; Fishwild D; Scannon P; Byers V Blood; 1991 Sep; 78(5):1173-82. PubMed ID: 1878584 [TBL] [Abstract][Full Text] [Related]
4. A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus. Stafford FJ; Fleisher TA; Lee G; Brown M; Strand V; Austin HA; Balow JE; Klippel JH J Rheumatol; 1994 Nov; 21(11):2068-70. PubMed ID: 7532717 [TBL] [Abstract][Full Text] [Related]
5. Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: effect on peripheral blood mononuclear cells and in vitro immune function. Fishwild DM; Strand V J Rheumatol; 1994 Apr; 21(4):596-604. PubMed ID: 7518519 [TBL] [Abstract][Full Text] [Related]
6. Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team. Skyler JS; Lorenz TJ; Schwartz S; Eisenbarth GS; Einhorn D; Palmer JP; Marks JB; Greenbaum C; Saria EA; Byers V J Diabetes Complications; 1993; 7(4):224-32. PubMed ID: 7693056 [TBL] [Abstract][Full Text] [Related]
7. Escape mechanisms of human leukemic cells to long-term immunotoxin treatment in an in vitro experimental model. Chignola R; Pasti M; Candiani C; Franceschi A; Anselmi C; Tridente G; Colombatti M Int J Cancer; 1995 May; 61(4):535-41. PubMed ID: 7538979 [TBL] [Abstract][Full Text] [Related]
8. In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain. Rostaing-Capaillon O; Casellas P Cancer Immunol Immunother; 1991; 34(1):24-30. PubMed ID: 1722138 [TBL] [Abstract][Full Text] [Related]
9. Four ricin chain A-based immunotoxins directed against the common chronic lymphocytic leukemia antigen: in vitro characterization. Faguet GB; Agee JF Blood; 1993 Jul; 82(2):536-43. PubMed ID: 7687163 [TBL] [Abstract][Full Text] [Related]
10. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients. Durrant LG; Byers VS; Scannon PJ; Rodvien R; Grant K; Robins RA; Marksman RA; Baldwin RW Clin Exp Immunol; 1989 Feb; 75(2):258-64. PubMed ID: 2784738 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia. Fishwild DM; Aberle S; Bernhard SL; Kung AH Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534 [TBL] [Abstract][Full Text] [Related]
13. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937 [TBL] [Abstract][Full Text] [Related]
19. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins. Manske JM; Buchsbaum DJ; Vallera DA J Immunol; 1989 Mar; 142(5):1755-66. PubMed ID: 2465347 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]